Teva Pharmaceutical Industries Limited (TEVA)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-07-29) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-04-29) · 99.1 · 99.2 | ||
| 10-KLatest | FY-2025 | 8-K (2026-01-28) · 99.1 | 8-K (2026-01-12) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-05) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-07-30) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-07) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-01-29) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-06) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-07-31) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-08) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-01-31) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-08) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover Page | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Income (loss) | ||
| Consolidated Statements of Income (loss) (P) | — |
|
| Consolidated Statements of Comprehensive Income (loss) | ||
| Consolidated Statements of Comprehensive Income (loss) (P) | — |
|
| Consolidated Statements of Changes In Equity | ||
| Consolidated Statements of Cash Flows (P) | ||
| Consolidated Statements of Changes In Equity (P) | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accumulated Other Comprehensive Income (loss) | — |
|
| Basis of Presentation | — |
|
| Certain Transactions | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Debt Obligations | ||
| Derivative Instruments and Hedging Activities | ||
| Earnings (loss) Per Share | ||
| Equity | — |
|
| Fair Value Measurement | ||
| Financial Expenses, Net | — |
|
| Goodwill | ||
| Identifiable Intangible Assets | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Inventories | ||
| Leases | — |
|
| Legal Settlements and Loss Contingencies | ||
| Long-term Employee-related Obligations | — |
|
| Other Assets Impairments, Restructuring and Other Items | ||
| Other Income | — |
|
| Pay Vs Performance Disclosure | ||
| Property, Plant and Equipment | — |
|
| Quarterly Financial Data (unaudited) | — |
|
| Redeemable Non-controlling Interests | ||
| Revenue From Contracts With Customers | ||
| Schedule of Valuation and Qualifying Accounts | — |
|
| Segments | ||
| Significant Accounting Policies | — |
|